Research ArticleClinical Studies
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
TOSHIFUMI YAMAGUCHI, SATORU IWASA, KENGO NAGASHIMA, NOBUAKI IKEZAWA, TETSUYA HAMAGUCHI, HIROKAZU SHOJI, YOSHITAKA HONMA, ATSUO TAKASHIMA, NATSUKO OKITA, KEN KATO, YASUHIDE YAMADA and YASUHIRO SHIMADA
Anticancer Research July 2016, 36 (7) 3531-3536;
TOSHIFUMI YAMAGUCHI
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
SATORU IWASA
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
KENGO NAGASHIMA
2Chiba University Hospital Clinical Research Center, Chiba, Japan
NOBUAKI IKEZAWA
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
TETSUYA HAMAGUCHI
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
HIROKAZU SHOJI
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
YOSHITAKA HONMA
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
ATSUO TAKASHIMA
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
NATSUKO OKITA
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
KEN KATO
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
YASUHIDE YAMADA
1Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
YASUHIRO SHIMADA
3Department of Medical Oncology, Kochi Health Sciences Center, Kochi, Japan
In this issue
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
TOSHIFUMI YAMAGUCHI, SATORU IWASA, KENGO NAGASHIMA, NOBUAKI IKEZAWA, TETSUYA HAMAGUCHI, HIROKAZU SHOJI, YOSHITAKA HONMA, ATSUO TAKASHIMA, NATSUKO OKITA, KEN KATO, YASUHIDE YAMADA, YASUHIRO SHIMADA
Anticancer Research Jul 2016, 36 (7) 3531-3536;
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
TOSHIFUMI YAMAGUCHI, SATORU IWASA, KENGO NAGASHIMA, NOBUAKI IKEZAWA, TETSUYA HAMAGUCHI, HIROKAZU SHOJI, YOSHITAKA HONMA, ATSUO TAKASHIMA, NATSUKO OKITA, KEN KATO, YASUHIDE YAMADA, YASUHIRO SHIMADA
Anticancer Research Jul 2016, 36 (7) 3531-3536;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Comparative Effectiveness of Cetuximab Versus Panitumumab in Patients With Metastatic Colorectal Cancer: A Nationwide Database Study
- Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer
- Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers